Loading...
Loading...
In a report published Friday, Bank of America analyst Derik de Bruin reiterated a Buy rating and $25.00 price target on
Bruker CorporationBRKR.
In the report, Bank of America noted, “On 11/26, BRKR announced that it received 510-k approval for its MALDI Biotyper CA System, a mass spectrometry based platform for the rapid identification and classification of microorganisms (bacteria, yeasts, and fungi), in-line with mgmt's expectation for a 2H13 approval. Of note, the FDA's approval is specifically for the identification of Gram negative bacterial colonies cultured from human specimens. However, BRKR is working on expanding clearance for Gram positive bacteria and fungi identification and plans to file one of these libraries with the FDA in 1H14.”
Bruker Corporation closed on Wednesday at $19.33.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in